Benjamin Bell

Benjamin Bell

Auto-generated profile, based on publicly available information

Benjamin Bell

McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Cell
Verified
Journal Article
Closed access
MTMasashi Tabuchi
Masashi Tabuchi
JMJoseph D. Monaco
Joseph D. Monaco
GDGrace Duan
Grace Duan
BBBenjamin Bell
Benjamin Bell
SLSha Liu
Sha Liu
MWMark N. Wu
Mark N. Wu

1 January 2017 in Current Biology
Verified
Journal Article
Closed access
JBJoseph L. Bedont
Joseph L. Bedont
TLTara A. LeGates
Tara A. LeGates
EBEthan Buhr
Ethan Buhr
ABAbhijith Bathini
Abhijith Bathini
JLJonathan P. Ling
Jonathan P. Ling
SBSeth Blackshaw
Seth Blackshaw

1 May 2018 in Trends in Genetics
Verified
Journal Article
Closed access
IBIan D. Blum
Ian D. Blum
BBBenjamin Bell
Benjamin Bell
MWMark N. Wu
Mark N. Wu

13 October 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
BBBenjamin J. Bell
Benjamin J. Bell
MMMedhinee M. Malvankar
Medhinee M. Malvankar
CTCarolyn Tallon
Carolyn Tallon
BSBarbara S. Slusher
Barbara S. Slusher

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MHMeixiang Huang
Meixiang Huang
CTCarolyn Tallon
Carolyn Tallon
BBBenjamin J Bell
Benjamin J Bell
Dimitrios KapogiannisDimitrios Kapogiannis
Dimitrios Kapogiannis
NHNorman J. Haughey
Norman J. Haughey
BSBarbara S. Slusher
Barbara S. Slusher
Background: Mounting evidence correlates the propagation of hyperphosphorylated tau (pTau) along synaptically connected networks in the brain with progressive cognitive decline in Alzheimer’s Disease (AD). Recent findings have highlighted extracellular vesicle (EV)s in enabling transcellular transmission of pathological tau and identified the partial inhibition of EV biogenesis via small‐molecule inhibitors of nSMase2 as a potential therapeutic avenue. However, there are no suitable compounds for clinical development so far.Method: Through high‐throughput screening, we identified PDDC, a highly selective and potent nSMase2 inhibitor with excellent brain penetration and oral bioavailability. To evaluate PDDC’s effect on tau propagation in vivo, we chronically administered PDDC‐containing chow to PS19 transgenic mice and measured brain ceramides, nSMase2 activity, tau levels, glial activation, hippocampal neuronal cell layer thickness, and mossy fiber synaptophysin staining. In addition, neuronally‐derived EVs from plasma were isolated and characterized. To directly monitor the effect of PDDC on tau propagation, we developed a murine model where an AAV encoding for P301L/S320F double mutant human tau was stereotaxically‐injected unilaterally into the hippocampus and transfer to the contralateral dentate gyrus (DG) was monitored ± PDDC treatment.Result: PS19 mice exhibited robust elevation of multiple ceramide species and nSMase2 enzymatic activity in the brain, both of which were normalized by PDDC treatment. PS19 mice treated with PDDC had significantly reduced hippocampal total tau and Thr181 pTau, reduced glial activation, protected synapses, and improved pyramidal and granule cell layer thickness. Plasma NEVs of treated mice were fewer in number and had lower p181‐Tau levels than the untreated group; FCA confirmed the decrease of NEVs carrying p262‐Tau at the single EV level. Similarly, the AAV‐hTau‐seeded mice treated with PDDC had reduced tau staining intensity in the contralateral DG.Conclusion: Data in two AD models using PDDC provides strong preclinical support for using nSMase2 inhibition as a therapeutic strategy to slow tau propagation in AD.